STOCK TITAN

Immuneering Names Dr. Igor Matushansky as Chief Medical Officer

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags

Immuneering (IMRX) has appointed Dr. Igor Matushansky as Chief Medical Officer to lead their clinical activities. Dr. Matushansky will oversee the ongoing Phase 2a study of IMM-1-104 in pancreatic cancer, lung cancer, and melanoma, as well as plans for a pivotal Phase 3 trial in pancreatic cancer.

The company plans to present updated data from the Phase 2a trial of IMM-1-104 in pancreatic cancer in Q2 2025. Earlier Phase 2a data from January showed promising results for first-line pancreatic cancer patients, suggesting improved efficacy and tolerability compared to standard care.

Dr. Matushansky brings extensive oncology experience from previous roles at Sail Biomedicines, Ipsen Pharmaceuticals, Hookipa Pharma, and Daiichi Sankyo. At Ipsen, he oversaw the NAPOLI-3 trial that led to NALIRIFOX's approval for first-line pancreatic cancer treatment.

Immuneering (IMRX) ha nominato il Dr. Igor Matushansky come Chief Medical Officer per guidare le loro attività cliniche. Il Dr. Matushansky supervisionerà lo studio Phase 2a di IMM-1-104 nel cancro pancreatico, nel cancro ai polmoni e nel melanoma, oltre ai piani per un trial cruciale di Fase 3 nel cancro pancreatico.

L'azienda prevede di presentare dati aggiornati dal trial di Fase 2a di IMM-1-104 nel cancro pancreatico nel Q2 2025. Dati precedenti della Fase 2a di gennaio hanno mostrato risultati promettenti per i pazienti con cancro pancreatico in prima linea, suggerendo un miglioramento dell'efficacia e della tollerabilità rispetto al trattamento standard.

Il Dr. Matushansky porta con sé una vasta esperienza in oncologia da ruoli precedenti in Sail Biomedicines, Ipsen Pharmaceuticals, Hookipa Pharma e Daiichi Sankyo. Presso Ipsen, ha supervisionato il trial NAPOLI-3 che ha portato all'approvazione di NALIRIFOX per il trattamento del cancro pancreatico in prima linea.

Immuneering (IMRX) ha nombrado al Dr. Igor Matushansky como Director Médico para liderar sus actividades clínicas. El Dr. Matushansky supervisará el estudio en curso Fase 2a de IMM-1-104 en cáncer de páncreas, cáncer de pulmón y melanoma, así como los planes para un ensayo pivotal de Fase 3 en cáncer de páncreas.

La empresa planea presentar datos actualizados del ensayo de Fase 2a de IMM-1-104 en cáncer de páncreas en Q2 2025. Datos anteriores de la Fase 2a de enero mostraron resultados prometedores para pacientes con cáncer de páncreas en primera línea, sugiriendo una mejor eficacia y tolerabilidad en comparación con el tratamiento estándar.

El Dr. Matushansky aporta una amplia experiencia en oncología de roles anteriores en Sail Biomedicines, Ipsen Pharmaceuticals, Hookipa Pharma y Daiichi Sankyo. En Ipsen, supervisó el ensayo NAPOLI-3 que condujo a la aprobación de NALIRIFOX para el tratamiento del cáncer de páncreas en primera línea.

Immuneering (IMRX)는 Dr. Igor Matushansky를 최고 의학 책임자로 임명하여 임상 활동을 이끌게 합니다. Matushansky 박사는 췌장암, 폐암 및 흑색종에 대한 IMM-1-104의 2a 단계 연구를 감독하며, 췌장암에 대한 중요한 3상 시험 계획도 관리합니다.

회사는 2025년 2분기에 췌장암에 대한 IMM-1-104의 2a 단계 시험에서 업데이트된 데이터를 발표할 계획입니다. 1월의 이전 2a 단계 데이터는 표준 치료에 비해 효과성과 내약성이 개선되었음을 시사하는 췌장암 1차 환자에 대한 유망한 결과를 보여주었습니다.

Matushansky 박사는 Sail Biomedicines, Ipsen Pharmaceuticals, Hookipa Pharma 및 Daiichi Sankyo에서의 이전 역할을 통해 광범위한 종양학 경험을 제공합니다. Ipsen에서 그는 NALIRIFOX의 췌장암 1차 치료 승인을 이끌었던 NAPOLI-3 시험을 감독했습니다.

Immuneering (IMRX) a nommé le Dr Igor Matushansky au poste de Directeur Médical pour diriger ses activités cliniques. Le Dr Matushansky supervisera l'étude en cours Phase 2a d'IMM-1-104 dans le cancer du pancréas, le cancer du poumon et le mélanome, ainsi que les projets pour un essai pivot de Phase 3 dans le cancer du pancréas.

L'entreprise prévoit de présenter des données mises à jour de l'essai de Phase 2a d'IMM-1-104 dans le cancer du pancréas au Q2 2025. Les données antérieures de la Phase 2a de janvier ont montré des résultats prometteurs pour les patients atteints de cancer du pancréas en première ligne, suggérant une amélioration de l'efficacité et de la tolérance par rapport aux soins standard.

Le Dr Matushansky apporte une vaste expérience en oncologie de ses précédents postes chez Sail Biomedicines, Ipsen Pharmaceuticals, Hookipa Pharma et Daiichi Sankyo. Chez Ipsen, il a supervisé l'essai NAPOLI-3 qui a conduit à l'approbation de NALIRIFOX pour le traitement du cancer du pancréas en première ligne.

Immuneering (IMRX) hat Dr. Igor Matushansky zum Chief Medical Officer ernannt, um ihre klinischen Aktivitäten zu leiten. Dr. Matushansky wird die laufende Phase 2a-Studie von IMM-1-104 bei Bauchspeicheldrüsenkrebs, Lungenkrebs und Melanom überwachen sowie die Pläne für eine entscheidende Phase 3-Studie bei Bauchspeicheldrüsenkrebs.

Das Unternehmen plant, aktualisierte Daten aus der Phase 2a-Studie von IMM-1-104 bei Bauchspeicheldrüsenkrebs im Q2 2025 zu präsentieren. Frühere Phase 2a-Daten aus Januar zeigten vielversprechende Ergebnisse für Patienten mit Bauchspeicheldrüsenkrebs in der ersten Linie und deuteten auf eine verbesserte Wirksamkeit und Verträglichkeit im Vergleich zur Standardbehandlung hin.

Dr. Matushansky bringt umfangreiche Onkologieerfahrung aus früheren Positionen bei Sail Biomedicines, Ipsen Pharmaceuticals, Hookipa Pharma und Daiichi Sankyo mit. Bei Ipsen überwachte er die NAPOLI-3-Studie, die zur Genehmigung von NALIRIFOX für die Behandlung von Bauchspeicheldrüsenkrebs in der ersten Linie führte.

Positive
  • Promising Phase 2a data showing improved efficacy and tolerability in pancreatic cancer treatment
  • Strategic expansion of clinical leadership with experienced CMO appointment
  • Advanced pipeline development with Phase 3 trial planning
Negative
  • None.

Industry veteran brings extensive oncology drug development expertise and experience in clinical treatment of cancer patients

Dr. Matushansky joins as Immuneering plans to present updated data from Phase 2a trial of IMM-1-104 in pancreatic cancer in Q2 2025

CAMBRIDGE, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Immuneering (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize more effective and better tolerated therapies for cancer patients, today announced that Igor Matushansky, MD, PhD, has joined the company as Chief Medical Officer. In this role, he will direct Immuneering’s clinical activities, providing medical and operational leadership for the company’s development programs including an ongoing Phase 2a study of lead program IMM-1-104 in pancreatic cancer, lung cancer, and melanoma, and plans to initiate a pivotal Phase 3 clinical trial in pancreatic cancer.

“The Phase 2a data we shared in January demonstrates the potential of IMM-1-104 to provide first line pancreatic cancer patients with a new option that is more effective and better tolerated than standard of care. Dr. Matushansky has dedicated his career to oncology – both as a researcher and as practicing oncologist working with cancer patients – and as a result, has a direct understanding of the patient experience,” said Ben Zeskind, Ph.D., CEO of Immuneering. “This is the perfect time to bring on a world-class CMO as we continue to execute our Phase 2a study and plan our pivotal study for IMM-1-104.”

“In my clinical practice, I have seen firsthand how vitally important quality of life is to cancer patients. Too often tolerability is an afterthought in oncology drug development. In clinical data thus far, Immuneering has demonstrated the potential for IMM-1-104 to profoundly improve tolerability and efficacy in treatment options for pancreatic cancer and other difficult-to-treat cancers,” Dr. Matushansky said. “I am very pleased to be joining this outstanding organization to help unlock the full potential of the company’s platform, and look forward to working with the company’s CSO Brett Hall and the entire Immuneering R&D team on the ongoing Phase 2a study, the planning and execution of a pivotal trial, and multiple other studies and programs in the months and years ahead.”

Dr. Matushansky was previously Chief Medical Officer at Sail Biomedicines (a Flagship Pioneering company), where he built and led the clinical/medical, translational, operational, and regulatory functions. Prior to that, he was SVP and Global Head of Oncology Development at Ipsen Pharmaceuticals, where, amongst many programs, he oversaw the completion of NAPOLI-3 leading to the approval of NALIRIFOX for first-line pancreatic cancer. Dr. Matushansky also served as Chief Medical Officer and Global Head of Research and Development at Hookipa Pharma, where he was responsible for bringing novel arenavirus technology from early preclinical to clinical proof-of-concept. He also served as Global Head of Oncology Early Development at Daiichi Sankyo, leading the company’s international research unit focused on early oncology therapeutic programs, and was Global Head at the Gene & Cell Therapy Unit and Global Clinical Program Head within the Oncology Translational Medicine Unit at Novartis. He began his career in academia at the Columbia University Medical Center, where he founded and directed a sarcoma center and ran a laboratory focused on the molecular basis of sarcomas. He earned his BA from Columbia University and his MD and a PhD in molecular biology at Albert Einstein College of Medicine. He performed his internal medicine residency at New York Presbyterian Hospital/Weill Cornell Medical Center and completed a fellowship in medical oncology and a post-doctoral research fellowship in cancer biology at the Memorial Sloan Kettering Cancer Center. Dr. Matushansky continues to dedicate time to taking care of sarcoma patients as an attending physician.

About Immuneering Corporation

Immuneering is a clinical-stage oncology company seeking to develop and commercialize more effective and better tolerated therapies for cancer patients. The Company’s lead product candidate, IMM-1-104, is an oral, once-daily deep cyclic inhibitor of MEK designed to improve tolerability and expand indications to include RAS-driven tumors such as most pancreatic cancers. IMM-1-104 is currently in a Phase 1/2a trial in patients with advanced solid tumors including pancreatic cancer. IMM-6-415 is an oral, twice-daily deep cyclic inhibitor of MEK currently in a Phase 1/2a trial in patients with advanced solid tumors harboring RAS or RAF mutations. The company’s development pipeline also includes several early-stage programs. For more information, please visit www.immuneering.com.

Forward-Looking Statements

This press release contains forward-looking statements, including within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding: Immuneering’s plans to develop, manufacture and commercialize its product candidates; the treatment potential of IMM-1-104, alone or in combination with other agents, including chemotherapy, checkpoint inhibitors and BRAF inhibitors; the plans and objectives of Company management for future operations, including with respect to the planning and execution of additional IMM-1-104 combination trials and potential pivotal trial of IMM-1-104 in combination with modified gemcitabine/nab-paclitaxel; and the timing for release of additional results from the Phase 2a portion of the trial for IMM-1-104.

These forward-looking statements are based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: the risks inherent in oncology drug research and development, including target discovery, target validation, lead compound identification, and lead compound optimization; we have incurred significant losses, are not currently profitable and may never become profitable; our projected cash runway; our need for additional funding and ability to continue as a going concern; our unproven approach to therapeutic intervention; our ability to address regulatory questions and the uncertainties relating to regulatory filings, reviews and approvals; the lengthy, expensive, and uncertain process of clinical drug development, including potential delays in or failure to obtain regulatory approvals; our reliance on third parties and collaborators to conduct our clinical trials, manufacture our product candidates, and develop and commercialize our product candidates, if approved; failure to compete successfully against other drug companies; protection of our proprietary technology and the confidentiality of our trade secrets; potential lawsuits for, or claims of, infringement of third-party intellectual property or challenges to the ownership of our intellectual property; our patents being found invalid or unenforceable; costs and resources of operating as a public company; and unfavorable or no analyst research or reports.

These and other important factors discussed under the caption “Risk Factors” in our Quarterly Report on Form 10-Q for the period ended September 30, 2024, and our other reports filed with the U.S. Securities and Exchange Commission, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

Media Contact:
Jenna Urban
jurban@cglife.com

Investor Contact:
Laurence Watts
619-916-7620
laurence@newstreetir.com


FAQ

What are the key clinical trials Immuneering (IMRX) is conducting for IMM-1-104?

Immuneering is conducting a Phase 2a study of IMM-1-104 in pancreatic cancer, lung cancer, and melanoma, with plans for a pivotal Phase 3 trial in pancreatic cancer.

When will Immuneering (IMRX) present updated Phase 2a data for IMM-1-104 in pancreatic cancer?

Immuneering plans to present updated data from the Phase 2a trial of IMM-1-104 in pancreatic cancer in Q2 2025.

What were the initial results of IMM-1-104 in pancreatic cancer treatment by IMRX?

Initial Phase 2a data from January showed IMM-1-104 has potential to be more effective and better tolerated than standard of care for first-line pancreatic cancer patients.

What is Dr. Matushansky's experience in pancreatic cancer drug development at IMRX?

Prior to IMRX, at Ipsen Pharmaceuticals, Dr. Matushansky oversaw the NAPOLI-3 trial that led to NALIRIFOX's approval for first-line pancreatic cancer treatment.
Immuneering Corp

NASDAQ:IMRX

IMRX Rankings

IMRX Latest News

IMRX Stock Data

60.29M
27.23M
27.81%
14%
5.24%
Biotechnology
Pharmaceutical Preparations
Link
United States
CAMBRIDGE